A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response.
Twenty subjects with binge eating disorder were randomly assigned to flexible-dose fluvoxamine or placebo for 12 weeks. A significant reduction in binge frequency, Beck Depression Inventory scores and the eating concern, shape concern and weight concern subscales of the Eating Disorder Examination were noted for both fluvoxamine (n = 9) and placebo (n = 11) groups. There were no significant differences between fluvoxamine and placebo for any treatment outcome variables. The findings from this small trial contribute to the inconsistent results of antidepressant studies in binge eating disorder.
Pearlstein
T
T
Department of Psychiatry and Human Behavior, Women's Behavioral Health Program, Brown Medical School, 101 DudleyStreet, Providence, RI 02905, U.S.A. Teri.Pearlstein@brown.edu
Spurell
E
E
Hohlstein
L A
LA
Gurney
V
V
Read
J
J
Fuchs
C
C
Keller
M B
MB
D000328:Adult; D015992:Body Mass Index; D002032:Bulimia / Q000175:diagnosis / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D016666:Fluvoxamine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D012720:Severity of Illness Index
D016666:Fluvoxamine; D017367:Selective Serotonin Reuptake Inhibitors